These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 22172033

  • 21. Inhibitory effect of cantharidin on osteoclast differentiation and bone resorption.
    Kim MH, Shim KS, Kim SH.
    Arch Pharm Res; 2010 Mar; 33(3):457-62. PubMed ID: 20361312
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. New regulation mechanisms of osteoclast differentiation.
    Nakashima T, Takayanagi H.
    Ann N Y Acad Sci; 2011 Dec; 1240():E13-8. PubMed ID: 22360322
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. NFATc1: functions in osteoclasts.
    Zhao Q, Wang X, Liu Y, He A, Jia R.
    Int J Biochem Cell Biol; 2010 May; 42(5):576-9. PubMed ID: 20035895
    [Abstract] [Full Text] [Related]

  • 27. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway.
    Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH.
    Biochem Biophys Res Commun; 2006 Dec 08; 351(1):99-105. PubMed ID: 17052691
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ, Chang EJ, Kim HM, Lee SB, Kim HD, Su Kim G, Kim HH.
    Free Radic Biol Med; 2006 May 01; 40(9):1483-93. PubMed ID: 16632109
    [Abstract] [Full Text] [Related]

  • 30. Irreversible inhibition of RANK expression as a possible mechanism for IL-3 inhibition of RANKL-induced osteoclastogenesis.
    Khapli SM, Tomar GB, Barhanpurkar AP, Gupta N, Yogesha SD, Pote ST, Wani MR.
    Biochem Biophys Res Commun; 2010 Sep 03; 399(4):688-93. PubMed ID: 20691668
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1.
    Rohatgi N, Zou W, Collins PL, Brestoff JR, Chen TH, Abu-Amer Y, Teitelbaum SL.
    Blood Adv; 2018 Oct 09; 2(19):2467-2477. PubMed ID: 30266822
    [Abstract] [Full Text] [Related]

  • 33. Lyn inhibits osteoclast differentiation by interfering with PLCgamma1-mediated Ca2+ signaling.
    Yoon SH, Lee Y, Kim HJ, Lee ZH, Hyung SW, Lee SW, Kim HH.
    FEBS Lett; 2009 Apr 02; 583(7):1164-70. PubMed ID: 19285079
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
    Iwai K, Koike M, Ohshima S, Miyatake K, Uchiyama Y, Saeki Y, Ishii M.
    J Bone Miner Res; 2007 Oct 02; 22(10):1612-20. PubMed ID: 17576169
    [Abstract] [Full Text] [Related]

  • 37. The mechanism of osteoclast differentiation induced by IL-1.
    Kim JH, Jin HM, Kim K, Song I, Youn BU, Matsuo K, Kim N.
    J Immunol; 2009 Aug 01; 183(3):1862-70. PubMed ID: 19587010
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of titanium particle-induced osteoclastogenesis through inactivation of NFATc1 by VIVIT peptide.
    Liu F, Zhu Z, Mao Y, Liu M, Tang T, Qiu S.
    Biomaterials; 2009 Mar 01; 30(9):1756-62. PubMed ID: 19118894
    [Abstract] [Full Text] [Related]

  • 39. The role of NFAT in osteoclast formation.
    Takayanagi H.
    Ann N Y Acad Sci; 2007 Nov 01; 1116():227-37. PubMed ID: 18083930
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.